Mobile

A randomised, open -label, parallel-group, international, multicenter phase III study of oral ZD1839 (IRESSA) versus intravenous docetaxel (Taxotere) in patients with locally advanced or metastatic re...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-002943-28

A randomised, open -label, parallel-group, international, multicenter phase III study of oral ZD1839 (IRESSA) versus intravenous docetaxel (Taxotere) in patients with locally advanced or metastatic recurrent non small cell lung cancer who have previously received platinum based chemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare overall survival between ZD1839 and docetaxel

Critère d'inclusion

  • Locally advanced of metastatic recurrent non-small cell lung cancer

Liens